- Home
- STHO vs CRDF Comparison
STHO vs CRDF Comparison
Compare STHO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CRDF
- Stock Information
- Founded
- STHO N/A
- CRDF 1999
- Country
- STHO United States
- CRDF United States
- Employees
- STHO N/A
- CRDF N/A
- Industry
- STHO Real Estate
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- CRDF Health Care
- Exchange
- STHO Nasdaq
- CRDF Nasdaq
- Market Cap
- STHO 153.3M
- CRDF 133.5M
- IPO Year
- STHO N/A
- CRDF N/A
- Fundamental
- Price
- STHO $9.63
- CRDF $4.26
- Analyst Decision
- STHO
- CRDF Strong Buy
- Analyst Count
- STHO 0
- CRDF 3
- Target Price
- STHO N/A
- CRDF $10.33
- AVG Volume (30 Days)
- STHO 77.6K
- CRDF 4.3M
- Earning Date
- STHO 11-05-2024
- CRDF 11-07-2024
- Dividend Yield
- STHO N/A
- CRDF N/A
- EPS Growth
- STHO N/A
- CRDF N/A
- EPS
- STHO 6.15
- CRDF N/A
- Revenue
- STHO $117,752,000.00
- CRDF $688,000.00
- Revenue This Year
- STHO N/A
- CRDF $23.78
- Revenue Next Year
- STHO N/A
- CRDF N/A
- P/E Ratio
- STHO $1.51
- CRDF N/A
- Revenue Growth
- STHO 13.35
- CRDF 49.57
- 52 Week Low
- STHO $9.23
- CRDF $1.41
- 52 Week High
- STHO $15.31
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- STHO 18.97
- CRDF 60.25
- Support Level
- STHO $10.06
- CRDF $3.06
- Resistance Level
- STHO $10.47
- CRDF $5.64
- Average True Range (ATR)
- STHO 0.32
- CRDF 0.54
- MACD
- STHO -0.08
- CRDF 0.18
- Stochastic Oscillator
- STHO 5.77
- CRDF 59.17
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").